Psyence Biomedical Ltd. Common Shares (PBM)vsVertex Pharmaceuticals Inc (VRTX)
PBM
Psyence Biomedical Ltd. Common Shares
$2.43
0.00%
HEALTHCARE · Cap: $5.57M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 32.9% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
PBM
Avoid26
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for PBM.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : PBM
The strongest argument for PBM centers on Price/Book.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : PBM
The primary concerns for PBM are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
PBM profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
PBM carries more volatility with a beta of 0.36 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (66/100 vs 26/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Psyence Biomedical Ltd. Common Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Psyence Biomedical Ltd. (PBM) is an innovative biotechnology company at the forefront of harnessing the therapeutic potential of psychedelic compounds for mental health and wellness applications. Utilizing a vertically integrated model, the firm engages in the cultivation, formulation, and clinical research of psilocybin and other psychedelics, aiming to develop groundbreaking therapies that effectively tackle mental health challenges. With a robust intellectual property portfolio and a strong clinical pipeline, Psyence is strategically poised to lead in an evolving industry, benefiting from increasing societal acceptance and the urgent need for accessible mental health solutions.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?